In February, the Conference Forum will host Immuno-Oncology 360°, a two-day meeting in New York City devoted to the business aspects, clinical advances, and scientific data that will help transform the way cancer is treated.
Axel Hoos, M.D., Ph.D., a member of the Cancer Research Institute (CRI) Scientific Advisory Council, co-chairman of CRI's Cancer Immunotherapy Consortium, and vice president for oncology research and development at GlaxoSmithKline, is a lead advisor and co-chair of the IO-360 program. Hoos will also chair a panel discussion on “Driving Guidance for Clinical Endpoints in Immunotherapy.”
“Immunotherapy has undergone a very rapid change in just the past six months, and biopharma needs the information that will be beneficial to them in both clinical trials and partnering,” said Hoos. “This conference will deal with all of the things that business needs to know—who has partnered with whom, how has imaging and biomarkers been utilized in clinical trials, what the different modalities in immunotherapy are, and what combinations are being applied.”
There will also be several other members of CRI’s Scientific Advisory Council presenting on their research, including:
- Carl H. June, M.D., a CRI grantee, will present data on CAR T cell therapies
- Jedd D. Wolchok, M.D., Ph.D., an associate director of the Scientific Advisory Council and director of CRI’s clinical trials network, will discuss the combination of ipi + nivo in melanoma
- Michael Kalos, Ph.D., a former CRI postdoctoral fellow, will give an update on emerging biomarkers
Learn more about this conference and register today—and make sure to use the code CRI20 to receive 20% off the registration fee.